CareRx Aktie

CareRx reported its first annual profit for 2025 of $3.3 million, revenue growth to $370.2 million and adjusted EBITDA of $32.9 million. The adjusted EBITDA margin rose to 8.9% for the full year; the fourth quarter showed a net profit of $1.0 million. Net debt fell by 24% year‑on‑year to $27.1 million, and cash and cash equivalents amounted to $13.9 million. For 2026, management is targeting the organic intake of 6,000–8,000 beds and double‑digit adjusted EBITDA margins, but sees risks from regulatory approvals and competition reviews. » Plus sur de.investing.com

CareRx missed profit and revenue expectations in the second quarter of 2025, but showed improvement in adjusted EBITDA and maintained a stable share price. The company reported revenue of 91.4 million CAD and earnings per share of 0.011 CAD, both below forecasts, while the stock rose slightly by 0.35%. CareRx continues to focus on operational efficiency, growth in bed capacity, and plans to expand into Quebec. » Plus sur de.investing.com

CareRx recorded sequential revenue growth to $91.4 million in the second quarter of 2025 and returned to profitability with a net income of $0.6 million. Margin improvements were achieved through increased efficiency and cost savings, while a new leadership structure was introduced to support strategic priorities. The company expects further growth in the coming quarters driven by additional beds and a strong sales pipeline. » Plus sur de.investing.com